

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111

Serial Number: 09/757,824

Filing Date: January 9, 2001

Title: PTD MODIFIED PROTEINS

Page 2

Dkt: 875.043US1

38. [Previously Amended] The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase.
39. The polypeptide of claim 34, wherein the polypeptide is a secreted protein.
40. The polypeptide of claim 39, wherein the secreted protein is a growth factor or an anti-neoplastic protein.
41. The polypeptide of claim 40, wherein the growth factor is GDNF, NGF, BDNF, or NT3.
42. The polypeptide of claim 40, wherein the anti-neoplastic protein is an inhibitor of neovascularization, cell migration, or cell proliferation.
43. The polypeptide of claim 34, wherein the polypeptide is a nuclear protein.
44. The polypeptide of claim 43, wherein the nuclear protein is a transcription factor.
45. The polypeptide of claim 34, wherein the polypeptide is a cytoplasmic protein.
46. The polypeptide of claim 45, wherein the cytoplasmic protein is a cytotoxic agent.
47. The polypeptide of claim 34, wherein the PTD is Tat PTD.
48. The polypeptide of claim 47, wherein the Tat PTD is Tat₄₇₋₅₇.
- 49-61. [withdrawn]